POGO

icon-facebook

Satellite Manual

4.2.1 Inhaled Pentamidine

4.2.2 Intravenous Pentamidine

Purpose
The Registered Nurse administers Intravenous (IV) pentamidine to the patient for the prevention or treatment of Pneumocystis jiroveci formerly carinii, pneumonia (PCP or PJP).  PJP can be severe or fatal if not promptly treated.  It can affect the lungs as well as other parts of the body, including the skin and internal organs.

Overview
Pentamidine is an antiprotozoal agent commonly used as a second-line agent to help prevent the growth of Pneumocystis jiroveci pneumonia (PJP), a microorganism often found in the lungs of patients who are immunosuppressed. When deemed necessary, pentamidine may be given via the IV route to patients intolerant of the inhaled route.

Contraindications
Hypersensitivity to pentamidine isethionate or any component of the formulation.

Precautions
Concerns related to adverse effects:

  • Hypotension: Severe hypotension (some fatalities) has been observed, even after a single dose. More common with rapid IV administration. Monitor blood pressure during (and after) infusion.
  • QT prolongation: May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.

Disease-related concerns:

  • Haematologic disorders: anemia, leukopenia and/or thrombocytopenia have been reported.
  • Cardiovascular disorder: use with caution in patients with preexisting cardiovascular disease; hyper-/hypotension and arrhythmia, including ventricular tachycardia (eg, torsade de pointes) have been reported.
  • Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels
  • Hypocalcemia: use with caution
  • Hepatic or renal impairment – use with caution
  • Diabetes mellitus: monitor blood glucose daily on therapy and periodically thereafter
  • Extravasation: IV Pentamidine is an irritant with vesicant-like properties. Ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula in place); gently aspirate extravasated solution (DO NOT flush the line); remove cannula; elevate extremity. Apply dry warm compresses. Refer to extravasation guidelines for management of irritant extravasation.

Dosage and Administration
Children and Adolescents:  IV:  4 mg/kg/dose every two to four weeks.

Please refer to hospital policy on dilution and administration rate.  Administer by slow IV infusion over a period of at least 60-120 minutes at a final concentration of administration not to exceed 2 mg/ml. Rapid infusion causes hypotension.  If hypotension occurs, increase infusion time to 2 to 3 hours.

Monitoring

  • Determine Baseline Blood Pressure (BP) and heart rate. Repeat BP and heart rate during infusion at 15 minutes, 1 hour and 2 hours.
  • Emergency equipment for resuscitation must be immediately available.
  • Monitor IV site closely for redness, pain, swelling. (Extravasation can cause tissue necrosis and sloughing at site).
  • Ensure adequate hydration.
  • Side effects include (but not limited to): hypoglycemia (initially), hyperglycemia, hyperkalemia, hypocalcemia, renal/hepatic toxicity, rapid or irregular pulse, skin rash (Steven Johnson syndrome), fever, pancreatitis, nausea, vomiting, diarrhea.

Documentation
Document all exposures as per hospital policy.

References

  1. De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm 1986;43:1486-8.
  2. Kim SY, Dabb AA, Glenn DJ, et al “Intravenous Pentamidine is Effective as a Second Line Pneumocystis Pneumonia Prophylaxis in Pediatric Oncology Patients,” Pediatric Blood        Cancer, 2008, 50(4): 779-83.
  3. Lexi-Comp Select Drug Information from Lexi-Comp Online, Lexi-Comp Inc. Pentamidine: Drug Provided by UpToDate, Walthan, MA, 2005. Accessed June 18, 2015.
  4. NIOSH [2014]. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP.. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa­tional Safety and Health, DHHS (NIOSH)   Publication No. 2014-138 (Supersedes 2012-150).retrieved from: http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf 
  5. Pentamidine IV Fact Sheet. Rouge Valley Health System Paediatric IV Manual. Toronto, Rouge Valley Health Systems. Feb 2013. PDF
  6. Reynolds PM, MacLaren R, Mueller SW, er al. Management of extravasation injuries:  a focused evaluation of noncytotoxic medications.  Pharmacotherapy2014; 34(6): 617-32.

Primary author Ms. Patti Bambury, Grand River Hospital, Kitchener with input from Mr. Kaniska Young-Tai, The Hospital for Sick Children, Toronto, Ms. Denise Reniers, Children’s Hospital, London Health Sciences Centre and Mr. John Wiernikowski, McMaster Children’s Hospital, Hamilton Health Sciences Centre, Hamilton. Reviewed by POGO Satellite Manual Review Nursing Group, 2016 and the POGO Satellite Manual Review Pharmacy Working Group, 2016.

4.3 Antiemetics
Back to Top

In this Section

  • 1.1 History & Overview
  • 1.2 Acknowledgements
  • 1.3 Committees and Working Groups
  • 1.4 Satellite Manual Disclaimer
  • 2.1 Principles of Satellite Care
  • 2.2 Eligible Patients
    • 2.2.1 Children Eligible for Chemotherapy Administration in a Satellite Centre
    • 2.2.2 Children Not Eligible for Chemotherapy Administration in a Satellite Centre
    • 2.2.3 Children Eligible for the Management of Complications on a Satellite Centre
    • 2.2.4 Eligibility of Children Requiring Supportive Care
  • 2.3 Scope of Satellite Practice
    • 2.3.1 Implementation of Psychosocial Treatment Plan (Process for Communication)
    • 2.3.2 Limitations on Satellite Practice
  • 2.4 Advanced Satellite Practice
  • 3.1 Safe Handling, Administration and Disposal of Chemotherapy Agents
  • 3.2 Accidental Exposure/Spills
  • 3.3 Extravasation Management
    • 3.3.1 Sample Extravasation Documenting Tool
  • 3.4 Injecting SC Medication Via an Insuflon
  • 3.5 Chemotherapy Administration Reference List
  • 3.6 Central Venous Catheter Care
  • 3.7 Chemotherapy Quick Reference
    • 3.7.1 Rapid Hydration Document
    • 3.7.2 Provider Guide: Prevention and Management or Irinotecan induced Diarrhea
    • 3.7.3 Parent Handout: Prevention and Management of Irinotean induced diarrhea
    • 3.7.4 Capizzi Methotrexate
    • 3.7.5 Erwinia L-Asparaginase
  • 4.1 Management of Fever and Neutropenia
    • 4.1.1 Routine Order Sample Sheet
    • 4.1.2 Fever Cards (Sample)
    • 4.1.3 Criteria for low-risk designation. Risk categorization refers to risk of bacteremia and serious complications, including mortality.
  • 4.2 Pentamidine Administration
    • 4.2.1 Inhaled Pentamidine
    • 4.2.2 Intravenous Pentamidine
  • 4.3 Antiemetics
  • 4.4 Treatment of Varicella-Zoster Infections
  • 4.5 TPN Document
  • 4.6 Immunization of Children with Cancer
  • 4.7 Transfusion
  • 4.8 When to consult the Tertiary Centre
  • 5.1 Palliative Care Overview
  • 5.2 Communication
  • 5.3 Settings of Care
  • 5.4 Symptom Management
  • 5.5 End of Life
  • 5.6 When a Child Dies in the Satellite Centre
    • 5.6.1 Reconciling your grief
    • 5.6.2 Funeral arrangement checklist
    • 5.6.3 Helping Children who grieve
    • 5.6.4 Coping with the Holidays
    • 5.6.5 The grieve experience
  • 6.1 Goals and Objectives
  • 6.2 Participant Site Selection
    • 6.2.1 Tertiary Site Selection
    • 6.2.2 Community Site Selection
  • 6.3 POGO’s Roles
    • 6.3.1 PHIPA, Privacy and Research
  • 6.4 Funding
    • 6.4.1 Funding Support for Tertiary Activity
    • 6.4.2 Financial Support for Pediatric Oncology Community Activity
  • 6.5 Infrastructure and Formal Requirements
    • 6.5.1 Tertiary Partners’ Role in Provincial Pediatric Oncology Satellite Program
    • 6.5.2 Satellite Partners’ Role in Provincial Pediatric Oncology Satellite Program
  • 7.1 Preamble
  • 7.2 Investigator responsibilities
  • 7.3 Training Requirements
    • 7.3.1 General Training for Conduct of Research
    • 7.3.2 Protocol Specific Training
  • 7.4 Research Activites that may be completed in satellite centres under supervision of DSI
  • 7.5 Research Activities to be completed in Tertiary Centres Only
  • 7.6 Recognition and Reporting of Adverse Events (AEs)
  • 7.7 Data Transfer
  • 7.8 Pharmacy Drug Accountibility
  • 7.9 Site Inspections and Quality Assurance
  • 8.1 Pediatric Oncology Shared Care Initial Data Transfer Sheet
  • 8.2 Shuttle Sheet
  • 8.3 Psychosocial Communication Tool
  • 9.1 Satellite Readiness/ Preparedness Checklist
  • 9.2 Education Report for Tertiary Centres
  • 9.3 Education Report for Satellite Centres
  • 9.4 Vital Signs Report
  • 9.5 Self- Assessment
  • 9.6 Satellite Contact Form
  • 9.7 Annual Satellite Caseload Report
  • 9.8 POGO Provincial Satellite Program Annual Accounting Report
Back to table of contents
Search our Manual
Have a question?
Contact us at: satellite@pogo.ca
  • About Us
    • Diversity, Equity, Inclusion
    • Childhood Cancer Care Plan
    • Our Mission and Vision
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • History & Milestones
    • Reports
    • Newsroom
    • Job Opportunities
    • Accessibility
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Childhood Cancer Resource Guide
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO AfterCare Education Day
    • POGO Multi-Disciplinary Symposium on Childhood Cancer
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2020 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 | Contact Us
1-855-FOR POGO (367-7646) | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |